Gonzalo Recondo

B, Argentina

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 59 publications

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.

Journal: The New England journal of medicine
Published: June 02, 2025

Lung Cancer in Argentina.

Lung Cancer in Argentina.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: October 07, 2024

Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study.

Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study.

Journal: Translational lung cancer research
Published: September 23, 2024

The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease.

The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease.

Journal: Cancers
Published: July 12, 2024

Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy.

Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy.

Journal: Cancer metastasis reviews
Published: May 15, 2024

Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology.

Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology.

Journal: Therapeutic advances in medical oncology
Published: October 14, 2023

Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.

Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.

Journal: Clinical lung cancer
Published: August 22, 2023

The role of angiogenesis inhibitors associated with tyrosine kinase inhibitors in the first-line treatment for EGFR-mutated advanced lung cancer.

The role of angiogenesis inhibitors associated with tyrosine kinase inhibitors in the first-line treatment for EGFR-mutated advanced lung cancer.

Journal: Critical reviews in oncology/hematology
Published: June 15, 2023

Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study.

Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study.

Journal: Targeted oncology
Published: February 19, 2023

Argentine consensus recommendations for lung cancer screening programmes: a RAND/UCLA-modified Delphi study.

Argentine consensus recommendations for lung cancer screening programmes: a RAND/UCLA-modified Delphi study.

Journal: BMJ open
Published: February 03, 2023

Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer.

Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 14, 2022

Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC.

Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: December 08, 2022
Showing 1-12 of 59

Last Updated: 09/26/2026